Amneal bets bigger on biosimilars
- Q1 2026 revenue grew 4% to $723 million, while adjusted EBITDA grew 19%.
- The Kashiv deal adds 20-plus biosimilar programs and a new long-term growth pillar.
- Specialty revenue rose 23% in Q1, helped by $21 million of CREXONT sales.
- The price already expects better execution, so valuation is not the easy part of the story.
- Debt will rise after the deal, with net leverage expected at 3.7 times adjusted EBITDA.
A bigger biosimilar bet
Amneal has moved from a mostly generic drug story to a broader medicine platform. The key change is its agreement to buy Kashiv BioSciences for $750 million upfront. That deal would add a full biosimilar engine, from research and manufacturing to selling the drugs.
The bull case is now about four engines working at once: complex Affordable Medicines, CREXONT in Specialty, the Pfizer GLP-1 partnership, and the Kashiv biosimilar pipeline. Management also gave a 2030 revenue target of about $4.4 billion, up about $1.2 billion from 2026, with 70% EPS growth over the same period.
The near-term numbers help the case. In Q1 2026, revenue grew 4% to $723 million, adjusted EBITDA grew 19%, and Amneal raised its stand-alone 2026 guidance. Specialty was the standout, with revenue up 23% and CREXONT reaching $21 million in quarterly sales.
The bear case is not gone. The stock gets only a low valuation score in Finn because the market already gives Amneal credit for a cleaner growth story. Kashiv still needs to close, leverage is set to rise, biosimilar price pressure can be harsh, and the FDA warning letter at the Gujarat facility remains unresolved.
Three reported lines, one new pillar
Amneal reports three segments. Affordable Medicines is the largest. It develops, makes, and sells generic drugs, with more focus on harder products like injectables and inhaled medicines, where fewer rivals can compete.
Specialty sells branded drugs, mainly for brain and hormone-related diseases. This segment is smaller, but it matters because products like CREXONT can carry better margins than plain generics if doctors keep adopting them.
AvKARE distributes drugs, over-the-counter products, and medical supplies, mainly to U.S. government buyers. Amneal is moving this business away from lower-margin distribution sales, which can lower revenue but lift margins.
Kashiv would make biosimilars a core growth pillar. A biosimilar is a near-copy of a complex biologic drug after the original drug loses protection. These products can be large opportunities, but they require clinical, regulatory, manufacturing, and pricing execution over many years.
What Amneal sells
Affordable Medicines
This is Amneal's largest business, with about 280 product families. It includes many generic medicines and a growing focus on complex dosage forms.
CREXONT
CREXONT is a Parkinson's disease drug and the main growth driver in Specialty. It produced $21 million of revenue in Q1 2026.
RYTARY and UNITHROID
RYTARY for Parkinson's disease and UNITHROID for hypothyroidism are key branded products. RYTARY faces generic erosion risk, while UNITHROID has continued to add growth.
BREKIYA
BREKIYA is a DHE autoinjector for migraine. It is newer and adds another specialty launch to watch.
AvKARE government channel
AvKARE supplies pharmaceuticals and medical products, mainly tied to government channels. Amneal is shifting the mix away from lower-margin distribution work.
Biosimilars and Kashiv pipeline
The Kashiv deal would add more than 20 biosimilar programs. Near-term attention is on the XOLAIR biosimilar application, with later programs aimed at drugs such as ORENCIA, CIMZIA, KEYTRUDA, and OPDIVO.
Pfizer GLP-1 partnership
Amneal is a preferred global supplier and licensed commercial partner in select emerging markets for a GLP-1 portfolio now tied to Pfizer. This is more of a long-term option than a current earnings driver.
Q1 revenue mix
Segment mix is based on Q1 2026 net revenue: Affordable Medicines at $423 million, Specialty at $133 million, and AvKARE at $166 million. Rounded shares use segment revenue totals, so they may not match total company revenue exactly.
What could go wrong
Kashiv integration misses
High impact · Medium oddsThe Kashiv deal changes Amneal's risk profile. Amneal must combine Kashiv's research and manufacturing with its own commercial system, then move more than 20 biosimilar programs through approval and launch. A slow close, poor handoff, or missed development timeline would hurt the main new growth story.
Higher debt limits room to move
High impact · Medium oddsThe Kashiv acquisition is expected to lift net leverage to 3.7 times adjusted EBITDA. Management wants leverage below 3.0 times by 2028. If EBITDA misses or launch costs rise, debt could limit buybacks, deals, or spending on new products.
Gujarat warning letter drags on
High impact · Medium oddsThe FDA warning letter for Amneal's Gujarat facility remains a key operating risk. The company says it is taking corrective actions, but the timeline and cost are still unclear. A slow fix could affect supply, inspections, or product approvals tied to the site.
Biosimilar price pressure
Medium impact · High oddsBiosimilars can be large markets, but they also attract strong competitors. If several rivals launch near the same time, payers can demand steep discounts. That could make the Kashiv pipeline less profitable than the headline market size suggests.
CREXONT growth cools
Medium impact · Medium oddsSpecialty growth depends heavily on CREXONT keeping its early momentum. The Q1 2026 launch data were strong, but expectations are now higher. If doctors or patients do not keep switching, Specialty growth could slow while RYTARY faces erosion.
In one breath
What does Amneal Pharmaceuticals do?
Amneal makes and sells affordable generic medicines, branded specialty drugs, and products for government channels. It is also building a larger biosimilar business through the planned Kashiv acquisition.
Why is the Kashiv deal important for AMRX?
Kashiv would give Amneal a deeper biosimilar pipeline and more control over research, manufacturing, and selling. Management says the combined portfolio targets more than $100 billion of U.S. opportunity.
What is CREXONT?
CREXONT is a branded Parkinson's disease medicine. It is important because it drove much of the Specialty segment's Q1 2026 growth and produced $21 million of revenue in the quarter.
What should AMRX investors watch next?
The main items are the Kashiv deal closing, CREXONT sales, FDA action on the XOLAIR biosimilar, and progress on the Gujarat warning letter. Debt after the deal also matters because leverage is expected to rise.